
|Articles|March 1, 2004
Satisfactory response
Washington - Etanercept can be safely administered to AIDS patients with difficult-to-treat inflammatory conditions, according to Robert Wallis, associate professor of medicine at UMDNJ-NJMS, who presented a poster at the February 2004 AAD meeting describing results of a Phase I trial conducted in Kampala, Uganda. "There does not appear to be a substantial risk that either opportunistic infections or HIV disease will be deleteriously affected by this treatment," said Dr. Wallis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Harrison Nguyen, MD, MBA, MPH’s Deep Dive into CSU, Vasculitis, and Autoimmune Blisters
2
Day 3 Recap: SDPA Fall 2025
3
From TikTok to Targeted Therapy: Shannon Trotter, DO, on Modern Dermatology Challenges
4
Q&A: Why Oncologist-Dermatologist Collaboration is Essential for Managing Systemic Mastocytosis
5



















